← Back
Data updated: Mar 10, 2026
SENTISS
OphthalmologyCardiovascularDermatology
SENTISS is a generic drug manufacturer focused on Ophthalmology, Cardiovascular, Dermatology.
1996
Since
9
Drugs
-
Trials
35
Approved (2yr)
Key Drugs
Recent Activity
CIPROFLOXACIN AND DEXAMETHASONE 2026-01-06
ALBUTEROL SULFATE 2025-12-01
ALBUTEROL SULFATE 2025-11-21
Labeling
LIDOCAINE HYDROCHLORIDE 2025-10-02
Manufacturing (CMC)
LIDOCAINE HYDROCHLORIDE 2025-09-26
Labeling
ERYTHROMYCIN 2025-09-23
LIDOCAINE HYDROCHLORIDE 2025-08-27
Manufacturing (CMC)
LIDOCAINE HYDROCHLORIDE 2025-08-22
Labeling
LIDOCAINE HYDROCHLORIDE 2025-08-22
Labeling
LIDOCAINE HYDROCHLORIDE 2025-07-29
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 50%
2 drugs
Cardiovascular 25%
1 drugs
Dermatology 25%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Cardiovascular, Dermatology, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology, Dermatology
B BRAUN specialty
Ophthalmology, Dermatology, Cardiovascular
BAUSCH specialty
Dermatology, Ophthalmology, Cardiovascular
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Dermatology
Active (8)
Discontinued (1)
Company Info
- First Approval
- 1996-07-18
- Latest
- 2025-08-27
- Applications
- 11